The Phox2 pathway is differentially expressed in neuroblastoma tumors, but no mutations were found in the candidate tumor suppressor gene PHOX2A

International Journal of Oncology

Volumn 34, Issue 3, 2009, Pages 697-705

  Wilzén, Annica ^a   Nilsson, Staffan ^b   Sjöberg, Rose Marie ^a   Kogner, Per ^c   Martinsson, Tommy ^a   Abel, Frida ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Child; Noradrenergic; Vesicular monoamine transporter 1

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; CARRIER PROTEIN; DOPAMINE BETA MONOOXYGENASE; PAIRED HOMEOBOX 2A PROTEIN; PAIRED HOMEOBOX 2B PROTEIN; PROTEIN SLC6A2; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR GATA 3; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 1;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHROMOSOME 11Q; CONTROLLED STUDY; DNA SEQUENCE; GENE EXPRESSION; GENE LOCATION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HOMEODOMAIN PROTEINS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEUROBLASTOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 64549126547     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000196     Document Type: Article

References (39)

1. Brodeur GM: Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216, 2003.
2. Brodeur GM, Sekhon G and Goldstein MN: Chromosomal aberrations in human neuroblastomas. Cancer 40: 2256-2263, 1977.
3. Spitz R, Hero B, Simon T and Berthold F: Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res 12: 3368-3373, 2006.
4. Guo C, White PS, Weiss MJ, et al: Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 18: 4948-4957, 1999.
5. Maris JM, Guo C, White PS, et al: Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma. Med Pediatr Oncol 36: 24-27, 2001.
6. Mosse Y, Greshock J, King A, Khazi D, Weber BL and Maris JM: Identification and high-resolution mapping of a constitutional 11q deletion in an infant with multifocal neuroblastoma. Lancet Oncol 4: 769-771, 2003.
7. Krona C, Caren H, Sjoberg RM, et al: Analysis of neuroblastoma tumour progression; loss of PHOX2B on 4p13 and 17q gain are early events in neuroblastoma tumourigenesis. Int J Oncol 32: 575-583, 2008.
8. Mosse YP, Laudenslager M, Khazi D, et al: Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet 75: 727-730, 2004.
9. Trochet D, Bourdeaut F, Janoueix-Lerosey I, et al: Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet 74: 761-764, 2004.
10. van Limpt V, Schramm A, van Lakeman A, et al: The Phox2B homeobox gene is mutated in sporadic neuroblastomas. Oncogene 23: 9280-9288, 2004.
11. Huber K, Karch N, Ernsberger U, Goridis C and Unsicker K: The role of Phox2B in chromaffin cell development. Dev Biol 279: 501-508, 2005.
12. Pattyn A, Goridis C and Brunet JF: Specification of the central noradrenergic phenotype by the homeobox gene Phox2b. Mol Cell Neurosci 15: 235-243, 2000.
13. Flora A, Lucchetti H, Benfante R, Goridis C, Clementi F and Fornasari D: Sp proteins and Phox2b regulate the expression of the human Phox2a gene. J Neurosci 21: 7037-7045, 2001.
14. Lo L, Tiveron MC and Anderson DJ: MASH1 activates expression of the paired homeodomain transcription factor Phox2a, and couples pan-neuronal and subtype-specific components of autonomic neuronal identity. Development 125: 609-620, 1998.
15. Brunet JF and Pattyn A: Phox2 genes - from patterning to connectivity. Curr Opin Genet Dev 12: 435-440, 2002.
16. Rychlik JL, Hsieh M, Eiden LE and Lewis EJ: Phox2 and dHAND transcription factors select shared and unique target genes in the noradrenergic cell type. J Mol Neurosci 27: 281-292, 2005.
17. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11: 1466-1477, 1993.
18. Martinsson T, Sjoberg RM, Hallstensson K, Nordling M, Hedborg F and Kogner P: Delimitation of a critical tumour suppressor region at distal 1p in neuroblastoma tumours. Eur J Cancer 33: 1997-2001, 1997.
19. Martinsson T, Sjoberg RM, Hedborg F and Kogner P: Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. Cancer Res 55: 5681-5686, 1995.
20. Carén H, Erichsen J, Olsson L, et al: High-resolution array copy number analyses and MLPA for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors; Four cases of homozygous deletions of the CDKN2A gene. BMC Genomics 9: 353, 2008.
21. Nakano M, Yamada K, Fain J, et al: Homozygous mutations in ARIX(PHOX2A) result in congenital fibrosis of the extraocular muscles type 2. Nat Genet 29: 315-320, 2001.
22. Vandesompele J, De Preter K, Pattyn F, et al: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: Research0034, 2002.
23. Guillemot F and Joyner AL: Dynamic expression of the murine Achaete-Scute homologue Mash-1 in the developing nervous system. Mech Dev 42: 171-185, 1993.
24. Hirsch MR, Tiveron MC, Guillemot F, Brunet JF and Goridis C: Control of noradrenergic differentiation and Phox2a expression by MASH1 in the central and peripheral nervous system. Development 125: 599-608, 1998.
25. Chen S, Ji M, Paris M, Hullinger RL and Andrisani OM: The cAMP pathway regulates both transcription and activity of the paired homeobox transcription factor Phox2a required for development of neural crest-derived and central nervous system-derived catecholaminergic neurons. J Biol Chem 280: 41025-41036, 2005.
26. Anderson DJ, Carnahan JF, Michelsohn A and Patterson PH: Antibody markers identify a common progenitor to sympathetic neurons and chromaffin cells in vivo and reveal the timing of commitment to neuronal differentiation in the sympathoadrenal lineage. J Neurosci 11: 3507-3519, 1991.
27. Oberthuer A, Warnat P, Kahlert Y, et al: Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease. Cancer Lett 250: 250-267, 2007.
28. Ohira M, Oba S, Nakamura Y, et al: Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 7: 337-350, 2005.
29. Wang Q, Diskin S, Rappaport E, et al: Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 66: 6050-6062, 2006.
30. Morin X, Cremer H, Hirsch MR, Kapur RP, Goridis C and Brunet JF: Defects in sensory and autonomic ganglia and absence of locus coeruleus in mice deficient for the homeobox gene Phox2a. Neuron 18: 411-423, 1997.
31. Stanke M, Junghans D, Geissen M, Goridis C, Ernsberger U and Rohrer H: The Phox2 homeodomain proteins are sufficient to promote the development of sympathetic neurons. Development 126: 4087-4094, 1999.
32. Pattyn A, Morin X, Cremer H, Goridis C and Brunet JF: The homeobox gene Phox2b is essential for the development of autonomic neural crest derivatives. Nature 399: 366-370, 1999.
33. De Preter K, Vandesompele J, Heimann P, et al: Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Biol 7: R84, 2006.
34. Huynh TT, Pacak K, Brouwers FM, et al: Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Eur J Endocrinol 153: 551-563, 2005.
35. Kolby L, Bernhardt P, Johanson V, et al: Can quantification of VMAT and SSTR expression be helpful for planning radionuclide therapy of malignant pheochromocytomas? Ann NY Acad Sci 1073: 491-497, 2006.
36. Jakobsen AM, Andersson P, Saglik G, et al: Differential expression of vesicular monoamine transporter (VMAT) 1 and 2 in gastrointestinal endocrine tumours. J Pathol 195: 463-472, 2001.
37. Revet I, Huizenga G, Chan A, et al: The MSX1 homeobox transcription factor is a downstream target of PHOX2B and activates the Delta-Notch pathway in neuroblastoma. Exp Cell Res 314: 707-719, 2008.
38. Amiel J, Laudier B, Attie-Bitach T, et al: Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome. Nat Genet 33: 459-461, 2003.
39. Weese-Mayer DE, Berry-Kravis EM, Zhou L, et al: Idiopathic congenital central hypoventilation syndrome: analysis of genes pertinent to early autonomic nervous system embryologic development and identification of mutations in PHOX2b. Am J Med Genet A 123: 267-278, 2003.